Insulet Corporation  

(Public, NASDAQ:PODD)   Watch this stock  
Find more results for podd
43.93
-1.14 (-2.53%)
Sep 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 43.58 - 45.30
52 week 23.94 - 45.60
Open 45.11
Vol / Avg. 0.00/427,311.00
Mkt cap 2.45B
P/E     -
Div/yield     -
EPS -1.08
Shares 57.27M
Beta 1.28
Inst. own 109%
Nov 3, 2016
Q3 2016 Insulet Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2016
Insulet Corp at Morgan Stanley Global Healthcare Conference
Sep 8, 2016
Insulet Corp at Robert W Baird Global Healthcare Conference - Webcast
Aug 16, 2016
Insulet Corp at Wedbush PacGrow Healthcare Conference - Webcast
Aug 3, 2016
Q2 2016 Insulet Corp Earnings Call - Webcast
Aug 3, 2016
Q2 2016 Insulet Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -4.98% -22.68%
Operating margin -1.47% -18.74%
EBITD margin - -13.86%
Return on average assets -6.74% -25.69%
Return on average equity -64.83% -124.74%
Employees 647 -
CDP Score - -

Address

600 Technology Park Dr Ste 200
BILLERICA, MA 01821-4126
United States - Map
+1-978-6007000 (Phone)
+1-978-6000120 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM). The Company purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The Company purchases OmniPods pursuant to its agreement with Flextronics. The OmniPod System is available in Europe, Canada and Israel.

Officers and directors

Michael L. Levitz Chief Financial Officer
Age: 41
Bio & Compensation  - Reuters
Daniel J. Levangie President - Insulet Drug Delivery
Age: 64
Bio & Compensation  - Reuters
Shacey Petrovic President -- Insulet Diabetes Products
Age: 41
Bio & Compensation  - Reuters
Bradley Thomas CFA Executive Vice President - Human Resources & Organizational Development
Age: 57
Bio & Compensation  - Reuters
Mark Licari Vice President - Global Manufacturing and Operations
Bio & Compensation  - Reuters
David Colleran J.D. Vice President, General Counsel
Bio & Compensation  - Reuters
Brittany Bradrick Vice President - Strategy and Corporate Development
Bio & Compensation  - Reuters
Trang Ly Vice President and Medical Director
Bio & Compensation  - Reuters
Patrick J. Sullivan President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
John A. Fallon M.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters